{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-152426","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2022-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.815617+00:00","generated_at":"2026-06-25T12:13:53.579087+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AVROBIO reports positive Phase 1/2 gene therapy data for cystinosis; all 5 patients off oral cysteamine","bullets":["All five dosed patients remain off oral cysteamine post gene therapy; no drug-related adverse events reported.","Early data show stabilization/improvement in visual motor integration, perception, and motor coordination scores (Beery VMI).","Cystine crystals reduced in skin (8-81%) and intestinal mucosa (28-83%) across patients 1-3 post gene therapy.","Photophobia scores improved or stable; patients #1,3,4,5 off cysteamine eye drops.","AVROBIO-sponsored trial planned to begin in 2023 after regulatory interactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-152426","json":"https://secwatch.observer/filing/0001193125-22-152426.json","markdown":"https://secwatch.observer/filing/0001193125-22-152426.md","text":"https://secwatch.observer/filing/0001193125-22-152426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312522152426/0001193125-22-152426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312522152426/d312223d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T12:13:53.579087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}